{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:36:48Z","timestamp":1762281408326,"version":"build-2065373602"},"reference-count":38,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004360"],"award-info":[{"award-number":["UM1TR004360"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R01DA059483"],"award-info":[{"award-number":["1R01DA059483"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,9]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Insomnia is a common complaint among patients with opioid use disorder (OUD) maintained on buprenorphine (BUP). However, people with OUD have historically been excluded from insomnia clinical trials, leaving clinicians without evidence-based treatment options for this patient population. Lemborexant, the Food and Drug Administration (FDA)-approved dual orexin receptor antagonist for the treatment of insomnia, was recently shown to be safe and tolerable among a sample of patients with insomnia who were maintained on BUP. We hypothesise that pharmacologically antagonising the orexin system with lemborexant may improve insomnia symptoms in individuals with OUD and also enhance BUP treatment benefits by improving performance in neurofunctional domains identified in the National Institute on Drug Abuse Phenotyping Assessment Battery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Participants with insomnia and OUD who have been stabilised on BUP for at least 4 weeks will be randomly assigned to receive either lemborexant (n=50) or placebo (n=50) for 8 weeks. Participants will complete assessments at baseline, during the 8-week intervention, postintervention and at a 2-week follow-up. Primary outcomes are insomnia severity and impulsivity. Secondary measures include objective sleep metrics (total sleep time, sleep efficiency, sleep onset latency and wake after sleep onset) and performance in the neurofunctional domains of negative emotionality and metacognition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study was approved by the Virginia Commonwealth University Institutional Review Board in April 2025 (protocol number HM20031777). Data collection began in May 2025 and is expected to be completed by May 2029. The trial is conducted under FDA IND no. 154797 (FGM). The dissemination plan for the trial includes presentations at local and national conferences, submission of primary and secondary outcome manuscripts for publication in peer-reviewed journals and circulation of findings to popular media outlets, as available. Results will also be shared with interested participants and clinical collaborators upon completion of the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"nct\" xlink:href=\"NCT06981195\">NCT06981195<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-108613","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:06:36Z","timestamp":1761725196000},"page":"e108613","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Neurofunctional phenotyping to investigate the role of the orexin system at the intersection of opioid use disorder and insomnia: a protocol for a randomised, placebo-controlled clinical trial of lemborexant in patients with insomnia receiving buprenorphine"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06981195","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8403-5395","authenticated-orcid":false,"given":"Madison M","family":"Marcus","sequence":"first","affiliation":[{"name":"Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia, USA"},{"name":"Institute for Womens Health, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Alattar","sequence":"additional","affiliation":[{"name":"Neurology, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[{"name":"Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Sabo","sequence":"additional","affiliation":[{"name":"Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Pignatello","sequence":"additional","affiliation":[{"name":"Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Ruddley","sequence":"additional","affiliation":[{"name":"Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber R","family":"Green","sequence":"additional","affiliation":[{"name":"Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayleigh","family":"Swan","sequence":"additional","affiliation":[{"name":"Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Keyser-Marcus","sequence":"additional","affiliation":[{"name":"Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick Gerard","family":"Moeller","sequence":"additional","affiliation":[{"name":"Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia, USA"},{"name":"Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA"},{"name":"Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin E","family":"Martin","sequence":"additional","affiliation":[{"name":"Institute for Womens Health, Virginia Commonwealth University, Richmond, Virginia, USA"},{"name":"Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"2025110323191533000_15.10.e108613.1","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1244156","article-title":"Patient reported preferences for sleep interventions among women receiving buprenorphine for opioid use disorder","volume":"14","author":"Eglovitch","year":"2023","journal-title":"Front Psychiatry"},{"key":"2025110323191533000_15.10.e108613.2","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000477"},{"key":"2025110323191533000_15.10.e108613.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2021.03.006"},{"key":"2025110323191533000_15.10.e108613.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2017.07.016"},{"key":"2025110323191533000_15.10.e108613.5","doi-asserted-by":"crossref","first-page":"108931","DOI":"10.1016\/j.drugalcdep.2021.108931","article-title":"Reregulation of cortisol levels and sleep in patients with prescription opioid use disorder during long-term residential treatment","volume":"227","author":"Mukherjee","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025110323191533000_15.10.e108613.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0465-x"},{"key":"2025110323191533000_15.10.e108613.7","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.905332","article-title":"Sex Specific Sleep Parameters Among People With Substance Use Disorder","volume":"13","author":"Martin","year":"2022","journal-title":"Front Psychiatry"},{"key":"2025110323191533000_15.10.e108613.8","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsad083","article-title":"Benzodiazepine, Z-drug, and sleep medication prescriptions in male and female people with opioid use disorder on buprenorphine and comorbid insomnia: an analysis of multistate insurance claims","volume":"46","author":"Martin","year":"2023","journal-title":"Sleep"},{"key":"2025110323191533000_15.10.e108613.9","doi-asserted-by":"crossref","first-page":"109508","DOI":"10.1016\/j.drugalcdep.2022.109508","article-title":"Patient-reported sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review","volume":"237","author":"Huhn","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"2025110323191533000_15.10.e108613.10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.sleep.2021.05.021","article-title":"A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem","volume":"84","author":"Wilkerson","year":"2021","journal-title":"Sleep Med"},{"key":"2025110323191533000_15.10.e108613.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2023.100195","article-title":"Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims","volume":"9","author":"Xu","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"key":"2025110323191533000_15.10.e108613.12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drugalcdep.2011.06.026","article-title":"Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial","volume":"120","author":"Stein","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"2025110323191533000_15.10.e108613.13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/ADM.0000000000000531","article-title":"A Pilot Crossover Trial of Sleep Medications for Sleep-disturbed Methadone Maintenance Patients","volume":"14","author":"Stein","year":"2020","journal-title":"J Addict Med"},{"key":"2025110323191533000_15.10.e108613.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2021.09.002"},{"key":"2025110323191533000_15.10.e108613.15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn8238","article-title":"Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper","volume":"14","author":"Huhn","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025110323191533000_15.10.e108613.16","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2024.100304","article-title":"Phase 1b\/2a safety study of lemborexant as an adjunctive treatment for insomnia to buprenorphine-naloxone for opioid use disorder: A randomized controlled trial","volume":"14","author":"Martin","year":"2025","journal-title":"Drug Alcohol Depend Rep"},{"key":"2025110323191533000_15.10.e108613.17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ajad.13170","article-title":"Development and Feasibility Study of an Addiction-Focused Phenotyping Assessment Battery","volume":"30","author":"Keyser-Marcus","year":"2021","journal-title":"Am J Addict"},{"key":"2025110323191533000_15.10.e108613.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304461","article-title":"Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder","volume":"19","author":"White","year":"2024","journal-title":"PLoS ONE"},{"key":"2025110323191533000_15.10.e108613.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-1872"},{"key":"2025110323191533000_15.10.e108613.20","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12921"},{"key":"2025110323191533000_15.10.e108613.21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/epirev\/mxaa009","article-title":"Assessment of Co-Occurring Substance Use During Opiate Treatment Programs in the United States","volume":"42","author":"Gormley","year":"2020","journal-title":"Epidemiol Rev"},{"key":"2025110323191533000_15.10.e108613.22","doi-asserted-by":"publisher","DOI":"10.1037\/a0030992"},{"key":"2025110323191533000_15.10.e108613.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(00)00065-4"},{"key":"2025110323191533000_15.10.e108613.24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5664\/jcsm.27286","article-title":"Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults","volume":"04","author":"Schutte-Rodin","year":"2008","journal-title":"J Clin Sleep Med"},{"key":"2025110323191533000_15.10.e108613.25","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19121284"},{"key":"2025110323191533000_15.10.e108613.26","doi-asserted-by":"publisher","DOI":"10.1037\/a0035973"},{"key":"2025110323191533000_15.10.e108613.27","doi-asserted-by":"crossref","first-page":"209037","DOI":"10.1016\/j.josat.2023.209037","article-title":"Delay discounting and substance use treatment outcomes: A systematic review focused on treatment outcomes and discounting methodology","volume":"149","author":"Exum","year":"2023","journal-title":"J Subst Use Addict Treat"},{"key":"2025110323191533000_15.10.e108613.28","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.1642"},{"key":"2025110323191533000_15.10.e108613.29","doi-asserted-by":"publisher","DOI":"10.1007\/s11031-005-7955-3"},{"key":"2025110323191533000_15.10.e108613.30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"2025110323191533000_15.10.e108613.31","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"2025110323191533000_15.10.e108613.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7967(03)00147-5"},{"key":"2025110323191533000_15.10.e108613.33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.sleep.2022.01.024","article-title":"Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder","volume":"90","author":"Roth","year":"2022","journal-title":"Sleep Med"},{"key":"2025110323191533000_15.10.e108613.34","doi-asserted-by":"publisher","DOI":"10.1037\/a0027391"},{"key":"2025110323191533000_15.10.e108613.35","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa034","article-title":"The effects of digital cognitive behavioral therapy for insomnia on cognitive function: a randomized controlled trial","volume":"43","author":"Kyle","year":"2020","journal-title":"Sleep"},{"key":"2025110323191533000_15.10.e108613.36","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.619674","article-title":"Change in Interpersonal and Metacognitive Skills During Treatment With Cognitive Behavioral Analysis System of Psychotherapy and Metacognitive Therapy: Results From an Observational Study","volume":"12","author":"Srig","year":"2021","journal-title":"Front Psychiatry"},{"key":"2025110323191533000_15.10.e108613.37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ajad.13194","article-title":"Sleep and substance use disorder treatment: A preliminary study of subjective and objective assessment of sleep during an intensive outpatient program","volume":"30","author":"Wilkerson","year":"2021","journal-title":"Am J Addict"},{"key":"2025110323191533000_15.10.e108613.38","doi-asserted-by":"crossref","unstructured":"Little RJ , Rubin DB . Statistical Analysis with Missing Data. John Wiley & Sons, 2019.","DOI":"10.1002\/9781119482260"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-108613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:31:46Z","timestamp":1762281106000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-108613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2025-108613"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-108613","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}